Annexin A2 antibodies in post-treatment Lyme disease.

IF 3.8 Q2 INFECTIOUS DISEASES Therapeutic Advances in Infectious Disease Pub Date : 2024-03-30 eCollection Date: 2024-01-01 DOI:10.1177/20499361241242971

John B Miller, Alison W Rebman, Marcia Daniela Villegas de Flores, Hong Wang, Erika Darrah, John N Aucott

{"title":"Annexin A2 antibodies in post-treatment Lyme disease.","authors":"John B Miller, Alison W Rebman, Marcia Daniela Villegas de Flores, Hong Wang, Erika Darrah, John N Aucott","doi":"10.1177/20499361241242971","DOIUrl":null,"url":null,"abstract":"Background: Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD).Objectives: Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies.Design and methods: Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD.Results: Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 versus 48.22 units, p < 0.0001), though with no difference in total symptom burden.Conclusion: Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"11 ","pages":"20499361241242971"},"PeriodicalIF":3.8000,"publicationDate":"2024-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10981857/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20499361241242971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Anti-annexin A2 (AA2) antibodies have been described in Lyme arthritis and erythema migrans, although they have not been described in post-treatment Lyme disease (PTLD).

Objectives: Determine whether anti-AA2 antibodies are present among patients with PTLD and determine the clinical relevance of these antibodies.

Design and methods: Anti-AA2 levels were tested serially in a longitudinal cohort of 44 patients with acute Lyme disease, 22 with a return to health (EM RTH), and 22 with PTLD. Anti-AA2 antibodies were also assessed in a cross-sectional group of 281 patients with PTLD.

Results: Anti-AA2 antibodies were highest after antimicrobial therapy in both the EM RTH and PTLD cohorts. By 6 months, there was no difference between EM RTH and healthy controls. Anti-AA2 antibodies were higher in the cross-sectional PTLD group (79.69 versus 48.22 units, p < 0.0001), though with no difference in total symptom burden.

Conclusion: Anti-AA2 persists in PTLD, though did not identify a clinical phenotype.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

治疗后莱姆病中的附录素 A2 抗体。

背景：抗附件素A2（AA2）抗体在莱姆关节炎和迁延性红斑中已有描述，但在治疗后莱姆病（PTLD）中还没有描述：确定PTLD患者中是否存在抗AA2抗体，并确定这些抗体的临床意义：设计：对44名急性莱姆病患者、22名恢复健康（EM RTH）患者和22名PTLD患者的抗AA2水平进行纵向队列连续检测。此外，还对281名PTLD患者的抗AA2抗体进行了横断面评估：结果：抗AA2抗体在EM RTH和PTLD患者抗菌治疗后最高。6个月后，EM RTH和健康对照组之间没有差异。PTLD横断面组的抗AA2抗体更高（79.69单位对48.22单位，P 结论：抗AA2抗体在PTLD中持续存在：抗AA2在PTLD中持续存在，但并未确定临床表型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊